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Abstract
Background: Hypertension is one of the major risk factors for cardiovascular morbidities, including coronary artery disease (CAD).
Objectives: With interest on the important role of hypertension in the progression of CAD, this study was designed to estimate the
effect of garlic powder tablets on the blood pressure (BP) in patients with severe CAD.
Methods: A randomized, placebo-controlled, clinical trial was conducted on 56 CAD patients, aged 25 - 75 years old. The patients
were randomly divided into two groups: Galois groups (n = 27), receiving garlic powder tablet (400 mg garlic) twice daily and the
placebo groups (n = 29), receiving placebo for 3 months. The BP was assessed at baseline and at the end of the study.
Results: During the 3 months study, in the placebo group, systolic BP (SBP) increased with 6.3 mmHg and diastolic BP (DBP) increased
with 4.6 mmHg, changes which were significant. After the 3 months, the effect of garlic on SBP, after adjusting for baseline value, was
significant, and this effect was more significant in hypertensive patients. Plasma lipids and lipoproteins did not change significantly
in either the garlic or placebo groups, during the study. Tolerability, compliance and acceptability were high in all patients.
Conclusions: These results demonstrate that treatment with garlic-based drugs can be an effective treatment for controlling BP
in CAD patients and has no interaction with other drugs that CAD patients take. Therefore, it may be considered as a safe adjunct
treatment for this group of patients.
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1. Background
Hypertension, which is defined as a systolic blood pres-
sure (SBP) > 140 mmHg or a diastolic blood pressure (DBP)
> 90 mmHg, is one of the major risk factors for cardiovas-
cular morbidities, including coronary artery disease (CAD)
(1).
By controlling BP in patients, one can control the pro-
gression of CAD. Hypertension affects one billion or one
in three adults worldwide. Unfortunately, more than 50%
of hypertensive individuals are unaware of their condition
(2). Management of hypertension should include relevant
lifestyle modifications, such as increased exercise, weight
loss and dietary changes, which could incorporate dietary
supplementation (2, 3).
Current medical therapy with standard antihyperten-
sive medication is not always effective and leads to a large
proportion of uncontrolled hypertension. In addition,
side effects of treatment may be influence treatment ad-
herence. For this reason, use of complementary and alter-
native therapies is high in patients (2).
Today’s therapeutic effects of dietary products pro-
mote the development of disease treatment on the basis
of natural products. Garlic has been used as both food
and medicine for thousands of years, although there was
little scientific support regarding its therapeutic proper-
ties, until recently (4, 5). Garlic contains at least 33 sulfur
compounds, 17 amino acids, several enzymes, vitamins and
minerals. Several of the sulfur-containing compounds,
such as allicin, ajoene, S-allylcysteine, S-methylcysteine, di-
allyl disulfide and sulfoxides, may be responsible for the
therapeutic effects of garlic (6, 7).
There are several garlic preparations on the market,
including raw or cooked garlic, garlic powder, garlic oil
and aged garlic extract. Dried garlic powder tablets are
very similar to fresh garlic, with respect to chemical com-
ponents. Like intact garlic cloves, dried garlic powder
contains alliin, the inactive precursor of the biologically
highly potent and strongly smelling allicin. The conver-
sion of alliin to allicin depends on an enzyme, alliinase,
which is present in fresh garlic, as well as in the dried gar-
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lic powder tablets (8). Emerging evidence suggests that dif-
ferent garlic preparations, or its active components, could
be useful for reducing cardiovascular risk and mortality
from heart disease, which is the most common disease in
the world (4, 9, 10). In the most of the previous studies
the effect of garlic on BP, have been performed in healthy
adults or hypertensive patients that took garlic supple-
ments without any medical drug during study. Conse-
quently, it is unclear whether standardized garlic prepara-
tions could provide a safe complementary treatment op-
tion for controlling BP in cardiovascular disease patients.
2. Objectives
With notice the important role of increased BP in the
progression of CAD and, also, beneficial effect of garlic on
health, here we assess the effect of garlic tablet, as an ad-
junct treatment, in patients with severe CAD that under-
gone angioplasty.
3. Methods
This study was a randomized, placebo-controlled, clin-
ical trial. Subjects with severe CAD, candidates for angio-
plasty, were recruited from the Rajaei cardiovascular medi-
cal and research center, Iran University of Medical Sciences,
Tehran, Iran, from August 2013 to April 2014. Inclusion cri-
teria were: patients with CAD with one, two or three vessel
stenosis, undergoing angioplasty, both men and women,
aged 25 - 75 years old and with a body mass index (BMI) <
30 kg/m2.
Exclusion criteria included: recent acute coronary syn-
drome (< 6 months), present smokers, diabetes, renal dis-
ease, BMI > 30 kg/m2, consistent use of garlic in the last
month and the use of antioxidant supplements. All sub-
jects gave written and informed consent and the study was
approved by the ethics committee of the national nutri-
tion and food technology research institute, Shahid Be-
heshti University of Medical Sciences, Tehran, Iran, regis-
tered under the number NCT01948453 at the clinical trials
registration (ClinicalTrials.gov).
Following the baseline assessment, patients were ran-
domized to receive either garlic powder tablet (equal to
400 mg garlic, 1200 µg allicin) twice daily or two placebo
tablets/day for 3 months, in adjunct to their prescribed
medications. Placebo tablets contained corn starch and
were visually identical to the garlic tablets. Simple ran-
domization was conducted using blocks of 10 sealed
opaque envelopes, assigning five patients to receive gar-
lic and five patients to receive placebo. Treatment was
started within 3 days following angioplasty. Participants
in the two groups received dietary advice from a trained
dietitian. The recommended diet was based on therapeu-
tic life style change diet (11), containing 25% energy derived
from fat, 20% from protein, and 55% from carbohydrate,
with energy content based on the calorie requirement for
weight maintenance that were estimated by the Miﬄin-St
Jeor equation (12). All subjects completed a take home 3-
day food recall (two weekdays and one weekend) at base-
line and end of intervention, and these records were ver-
ified by a nutritionist. Subjects’ height, weight and BMI
were measured at baseline and after the 3 months, by the
same study coordinator. Physical activity was measured by
physical activity questionnaire (13, 14) at baseline and after
the 3 months.
3.1. Blood Pressure Monitoring
Blood pressure was measured by a trained research
nurse, using a single calibrated mercury sphygmo-
manometer, with appropriate sized cuffs, at baseline
and after the 3 months. The BP measurements were taken
with the patient in a seated position, with their arm sup-
ported at heart level and after 5 minutes rest. The BP was
recorded as two serial measurements, at intervals of 5
minutes. The mean of the two BP measurements was used
in the analysis.
Hypertension was defined as SBP > 140 mmHg or DBP >
90 mm Hg, in a sitting position, on at least three different
occasions.
3.2. Laboratory Analysis
Fasting blood samples were taken before angioplasty
(baseline) and after 3 months. Laboratory measurements
included plasma total cholesterol, low-density lipoprotein
(LDL) cholesterol, high-density lipoprotein (HDL) choles-
terol and triglycerides, using commercially available kits
(Pars Azmoon Sanat Pooya, Tehran, Iran). The LDL choles-
terol was measured using a direct assay.
3.3. Statistical Analyses
Baseline characteristics for each of the two groups are
described using means and standard error for continuous
measures and percentages for dichotomous measures. For
continuous variables, the Kolmogorov-Smirnov test was
applied, to ensure normality. Baseline and post-treatment
parameters were compared using a paired t test and an
independent t-test for comparison of means between two
groups, at baseline. Analysis of covariance was used for
controlling of covariates (baseline value of triglycerides,
SBP and DBP). The correlations between factors were de-
termined by Pearson correlation coefficients. The level of
significance set for all statistical analyses was P < 0.05. All
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statistical analyses were performed using SPSS version 11.5
software (SPSS Inc., Chicago, IL, USA).
4. Results
Prior to randomization, two subjects withdrew, since
they returned to their own countries. Of the 70 subjects
enrolled in the study, 35 subjects were randomized to the
garlic group and 35 were randomized to the placebo (Fig-
ure 1). Fourteen subjects withdrew from the study follow-
ing randomization, with 27 subjects completing study in
the garlic group and 29 subjects in the placebo group.
Baseline characteristics were similar between the two
groups (Table 1). The mean age of 56 the subjects that com-
pleted the study was 59.37± 1.28 years old. The frequencies
of one, two and three vessel CAD were 61%, 35.1% and 3.9%,
respectively.
Table 1. Baseline Characteristics of the Patientsa
Variable Garlic Group (n =
27)
Placebo Group (n =
29)
P
Age, y 56.88± 1.67 61.68± 1.85 0.06
Sex,male, (%) 74.1 79.3 0.65
BodyWeight, Kg 74.70± 2.94 69.75± 2.0 0.16
BMI, kg/m2 26.09± 0.78 25.38± 0.54 0.45
PCI or CABG
History
6 (22.2) 2 (6.8) 0.21
CAD
Single Vessel
Disease
18 (66.7) 19 (65.5)
Two or Three
Vessel
Disease
9 (33.3) 10 (35.5) 0.47
Ejection
Fraction, (%)
46.11± 1.17 42.93± 1.60 0.13
Hyperten-
sion
8 (26.9) 11 (37.9) 0.34
Medications
Statins, n 27 29 -
Aspirin, n 27 29 -
Plavix, n 27 29 -
β-Blocker, n 25 29 0.30
ACE-I / ARB, n 27 29 -
Abbreviations: ACE-I, angiotensin converting enzyme inhibitor; ARB, an-
giotensin receptor blocker; BMI, body mass index; BP, blood pressure; CABG,
coronary artery bypass graft surgery; CAD, coronary artery disease; PCI, percu-
taneous coronary intervention.
aValues are expressed as mean± SE or No. (%) of subjects for dichotomous mea-
sures.
Plavix, aspirin, angiotensin-converting enzyme in-
hibitor / angiotensin receptor blocker, β-blocker and
Table 2. Daily Energy and Macronutrients Intake and Physical Activity in Patientsa
Variable Baseline 3-m Follow-up Pb
Physical activity, METs h/day
Garlic group (n = 8) 24.51± 1.17 24.26± 1.17 0.51
Placebo group (n = 11) 23.55± 1.29 23.31± 1.36 0.42
P 0.58 0.60
Energy, kcal
Garlic group (n = 27) 2547.1± 89.6 2566.1± 87.3 0.56
Placebo group (n = 29) 2397.8± 65.5 2450.± 71 0.07
Pb 0.17 0.30
Carbohydrate, gram
Garlic group (n = 27) 362.6± 15.4 365.1± 14.8 0.70
Placebo group (n = 29) 339± 11.2 347.3± 11.4 0.24
P 0.21 0.34
Protein, gram
Garlic group (n = 8) 114.5± 4.58 115± 4.44 0.71
Placebo group (n = 11) 108.1± 3.21 109.5± 3.67 0.65
P 0.25 0.29
Fat, gram
Garlic group (n = 8) 77.37± 2.05 80.36± 2.32 0.06
Placebo group (n = 11) 74.67± 1.95 76.54± 2.11 0.30
P 0.34 0.22
Abbreviations: BP, blood pressure; METs, metabolic equivalents.
aValues are expressed as mean± SEM.
bFor comparisons, t-test was performed
statins were prescribed to all 56 subjects of the study. There
were no differences in total daily calories and macronutri-
ent intake between groups, at the baseline of study, and,
also, within groups. Both groups consumed the recom-
mended diet (Table 2). There were no significant changes
in body weight after 3 months, between both groups.
At the beginning of the study, the mean SBP and DBP
of the 56 subjects that completed the study were 118.82±
2.01 and 75.53 ± 1.51 mmHg, respectively, and from 56 pa-
tients, 18 patients (32.1%) had hypertension. Also, there was
no statistical significant difference in the number of pa-
tients that had hypertension between the two groups (Ta-
ble 1).
After the 3 months, in the placebo group, SBP increased
by 6.3 mmHg (P = 0.002) while DBP increased by 4.6 mmHg
(P = 0.015) increased and these increases were not observed
in the garlic group (Table 3).
In our study, when the baseline value of SBP was in-
cluded as covariate in the analysis, the effect of garlic on
SBP was significant (Table 3). The effect of garlic on BP in
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Subjects Eligible After
Screening (n = 72)
Randomized (n = 70)
Withdrew Prior to
Randomization (n = 2)
Placebo Group,
Month 0 (n = 35)
Withdrawals (n = 6)
-lack of Consistent use
of Placebo Tablets (n = 2)
-Lost to Follow-up (n = 3)
-Dead Because of
Hospital Infection,
1 Month After PCI (n = 1)
Withdrawals (n = 8)
- Lack of Consistent use
of Garlic Tablet (n = 2)
-Lost to Follow-up (n = 5)
-Unable to Continue
Taking Garlic Tablet
(n = 1)
Garlic Group,
Month 0 (n = 35)
Garlic Group Month
3 (n = 27)
Placebo Group
Month 3 (n = 29)
Figure 1. Participant Flowchart
hypertensive patients, compared to patients with normal
BP, was more significant (P = 0.002). In secondary analyses,
we included only subjects that had hypertension at base-
line. In this group of patients, the mean changes in SBP
between the two groups before and, also, after adjusting
for baseline value of SBP, were significant (Table 3). In our
study, there was no significant correlation between SBP or
DBP and other CAD risk factors. In hypertensive patients,
SBP was marginally correlated directly with BMI (P = 0.08)
and DBP was correlated inversely with total cholesterol (P
= 0.02) and HDL cholesterol (P = 0.07).
There were significant differences in the baseline levels
of triglycerides between garlic and placebo groups (Table
4). No other significant baseline differences in the lipid,
or lipoprotein values, were observed. There were within-
group changes during therapy and, compared with base-
line, all parameters measured at the end of the study in-
creased, in both groups. There were no significant differ-
ences when mean changes in garlic-treated subjects were
compared with mean changes in placebo-treated subjects.
4.1. Tolerability and Acceptability
Most of the participants found taking the tablets easy
and acceptable. In the garlic group, one person had gas-
trointestinal complaints after 10 days of garlic tablet ad-
ministration and, for this reason, did not continue the
study. Most of the participants reported that they would
be willing to continue taking the tablets after the trial was
finished, if the treatment was effective.
5. Discussion
This trial suggests dry garlic powder tablet to be supe-
rior to placebo in lowering SBP in patients with severe CAD.
A dosage of two capsules daily, containing 800 mg of dried
garlic, significantly lowered SBP, compared with placebo,
over 3 months, and the dose was well tolerated and highly
acceptable.
The change in SBP, achieved in our study, is comparable
with the results of other successful trials.
Ried et al. (2), in their study, showed that supplemen-
tation with garlic capsules containing 480 mg of aged gar-
lic extract, for 12 weeks, lowered SBP by an average of 11.8
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Table 3. Blood Pressure in Patientsa
Variable Baseline 3-M Follow-Up Changes FromBaseline
All patients completed the study
SBP,mmHg
Garlic group (n = 27) 120± 3.0 121.1± 1.5 1.11± 2.6
Placebo group (n = 29) 117.6± 2.7 124± 1.6 6.31± 1.86
P 0.56 0.22 0.11
Adjusted Pb - 0.04 -
DBP,mmHg
Garlic group (n = 27) 74.7± 2.2 78.8± 1.1 4.11± 2.3
Placebo group (n = 29) 76.2± 2.0 80.8± 0.8 4.6± 1.7
P 0.63 0.16 0.86
Adjusted Pc - 0.19 -
Subgroup of patients with hypertension at baseline
SBP,mmHg
Garlic group (n = 8) 135.7± 2.96 123.5± 3.8 -12.1± 2.1
Placebo group (n = 11) 126.4± 4 129± 2.5 2.6± 2.6
P 0.11 0.22 0.001
Adjusted Pb - 0.005 -
DBP, mmHg
Garlic group (n = 8) 85.42± 3.9 81.42± 2.82 -4± 3.8
Placebo group (n = 11) 80.45± 2.4 81.81± 1.01 1.3± 2.6
P 0.27 0.88 0.24
Adjusted Pc - 0.65 -
Abbreviations: DBP, diastolic blood pressure; SBP, systolic blood pressure.
aValues are expressed as mean± SEM.
bFor comparisons, t-test was performed; Difference between groups in mean of SBP after adjusting for baseline SBP.
cDifference between groups in mean of DBP after adjusting for baseline DBP.
mmHg, in patients with uncontrolled systolic hyperten-
sion.
A meta-analysis of 10 trial studies of the effect of garlic
on SBP showed a significant difference between garlic and
control groups, with garlic having a greater effect in reduc-
ing SBP by 4.56 mmHg, compared with placebo (15).
Although several clinical trials have suggested that gar-
lic lowers SBP and/or DBP and has a beneficial effect in con-
trolling BP, negative results have also been obtained in cer-
tain of the trials. A meta-analysis of eight controlled trials,
with a total of 415 subjects, testing the same brand of dried
garlic tablets, showed only small reductions in blood pres-
sure. In this meta-analysis, only three of these trials were in
hypertensive patients (16). Also, Simons et al., in a system-
atic review of the influence of trial quality on the effect of
garlic on BP, concluded that the effect of garlic on BP can-
not be ascertained (17). One reason for different result in
studies may be related to dose variation or varied types of
garlic preparations (dried garlic powder, garlic oil or gar-
lic extract) that may contain widely varying types of sulfur-
containing phytochemicals due to the different methods
of producing the preparations.
Possible mechanisms of the antihypertensive action
of garlic can be related to its prostaglandin-like effects,
which decrease peripheral vascular resistance (16). Gar-
lic reduces prostaglandin E2 and thromboxane B2 lev-
els (18). Also, the gamma-glutamylcysteines are the com-
pounds in garlic that inhibit angiotensin-converting en-
zyme (19, 20). Garlic also inhibited endothelin-1 induced
contraction, in a dose-dependent manner (21). Allicin and
ajoene, in garlic, appear to inhibit inducible nitric oxide
synthase in macrophages, reducing nitrite accumulation
in atherosclerotic plaques and in hypoxic tissues (22, 23).
The population of our study included men and women
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Table 4. Plasma Lipoproteins and lipid Profile in Patients
Variable Baseline 3-M FollowUp Changes FromBaseline
Triglycerides,mg/dL
Garlic group 85.25± 9.8 122± 11.8 35.03± 9.62
3-m follow-up 56.24± 4.3 99.92± 7.9 42.78± 6.52
P 0.008 < 0.001a 0.31a
Cholesterol,mg/dL
Garlic group 108.1± 4.7 119.7± 5.0 11.8± 4.1
Placebo group 110.8± 5.4 129.1± 10.1 18.1± 6.2
Pb 0.71 0.41 0.41
LDL-C,mg/dL
Garlic group 54.18± 3.1 60.0± 3.2 6.1± 3.1
Placebo group 57.5± 3.7 66.2± 6.07 8.6± 3.7
P 0.49 0.38 0.61
HDL-C,mg/dL
Garlic group 33.2± 1.7 38.3± 1.8 5.1± 1.1
Placebo group 36.1± 1.5 41.7± 1.8 5.5± 1.6
P 0.23 0.19 0.85
Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
aAnalysis of covariance with baseline value, as covariate, was performed.
bFor comparisons, t-test was performed.
with severe CAD that undergone angioplasty and took gar-
lic tablet in adjunct to conventional medical treatment.
However, most of the previous studies have been per-
formed in healthy adults or subjects with hypertension
and without heart disease. Consequently, it was unclear
whether standardized garlic preparations could provide a
safe complementary treatment option for controlling BP
in cardiovascular disease patients.
No BMI change was observed in our investigation and
both groups received the same dietary advice and there
were no differences in total daily calories and macronutri-
ent intake, between groups.
In the present study, after 3 months, lipid and lipopro-
tein levels increased in both groups. However, this in-
creased trend was lower in garlic group, compared to
placebo group. The increase in lipid levels in our study
may be related to different dosing of statin prescribed to
patients before and after angioplasty. Based on the hospi-
tal management protocol of CAD patients undergoing an-
gioplasty, high dose (80 mg/day) of atorvastatin was pre-
scribed for all patients, for a period of 2 - 3 days before an-
gioplasty and a constant maintenance dose (20 mg/day)
for the rest of the study period. However, since the drug
therapy protocol was relatively similar in all patients, it ap-
pears that the impact of medication on patients of garlic or
placebo groups was equal.
In conclusion, the results of our study suggest that 3
months treatment with garlic-based drug provides to be
an effective and tolerable treatment for controlling BP in
CAD patients and may be considered as a safe adjunct treat-
ment for this group of patients.
Future large-scale trials are needed to investigate
whether standardized garlic preparations could provide a
safe complementary treatment option for controlling BP
in CAD patients, in clinical practice.
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